Fate Therapeutics (FATE) Cash from Operations (2012 - 2026)
Fate Therapeutics (FATE) posted Cash from Operations of 30822000.0 for Q1 2026, down 32.2% on a QoQ basis from 23314000.0 in Q4 2025, and up 8.83% year-over-year from 28319953.2 in Q1 2025.
Fate Therapeutics (FATE) Cash from Operations (2012 - 2026) Analysis & Trends
Fate Therapeutics' Cash from Operations history runs 15 years deep, the most recent figure standing at 30822000.0 for Q1 2026.
- Quarterly Cash from Operations rose 8.83% year-over-year to 30822000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 103097000.0 (up 16.41% YoY) and the FY2025 annual result came in at 106084000.0, up 13.66% from the prior year.
- Cash from Operations was 30822000.0 for Q1 2026 at Fate Therapeutics, down from 23314000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 23314000.0 in Q4 2025 and bottomed at 75389000.0 in Q4 2022.
- A 5-year average of 37661823.53 and a median of 32306000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 138.46% — and 2023, when it soared 55.33%.
- Fate Therapeutics' Cash from Operations stood at 75389000.0 in 2022, then surged by 51.4% to 36637000.0 in 2023, then rose by 24.12% to 27799000.0 in 2024, then increased by 16.13% to 23314000.0 in 2025, then sank by 32.2% to 30822000.0 in 2026.
- Business Quant data shows FATE's Cash from Operations at 30822000.0 in Q1 2026, 23314000.0 in Q4 2025, and 24374000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.17 Mn |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | -30.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.82 Mn |
| Mar 31, 2026 | -30.82 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Sep 30, 2025 | -24.37 Mn |
| Sep 30, 2025 | -24.37 Mn |
| Jun 30, 2025 | -24.59 Mn |
| Jun 30, 2025 | -24.59 Mn |
| Mar 31, 2025 | -33.81 Mn |
| Mar 31, 2025 | -33.81 Mn |
| Dec 31, 2024 | -27.80 Mn |
| Dec 31, 2024 | -27.80 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Jun 30, 2024 | -32.31 Mn |
| Jun 30, 2024 | -32.31 Mn |
| Mar 31, 2024 | -33.35 Mn |
| Mar 31, 2024 | -33.35 Mn |
| Dec 31, 2023 | -36.64 Mn |
| Dec 31, 2023 | -36.64 Mn |